

+

PTO/SB/05 (08/00)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No.

25636-718

Only for new nonprovisional applications under 37 CFR 1.53(b)

First Inventor or Application Identifier

Shao-bing Hua

Title

Human Monoclonal Antibody Against Conceptors For Human Immunodeficiency Virus

Express Mail Label No.

EL 713754131 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
 2. ☒ Applicant claims small entity status. See 37 CFR 1.27.
 3. ☒ Specification [Total Pages 65]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed-Sponsored R&D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Detailed Description of the Drawings
 - Detailed Description
 - Claim(s)
 4. ☒ Drawing(s) (37CFR 1.152) [Total Sheets 18]
 5. ☐ Oath or Declaration [Total Pages]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
 6. ☐ Application Data Sheet. See 37 CFR 1.76
 7. ☒ Microfilm Computer Program (Appendix)
 8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS) PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. /

Prior application information: Examiner _____ Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 021971 or ☐ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME _____

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Name (Print/Type)

Shirley Chen

Registration No. (Attorney/Agent)

44,608

Signature _____

Date _____

February 8, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Shao-bing Hua et al.) Group Art Unit: Unassigned
Application No. Unassigned) Examiner: Unassigned
Filed: Herewith)
For: Human Monoclonal Antibody Against)
Coreceptors For Human Immunodeficiency Virus)

STATEMENT UNDER 37 C.F.R. 1.821(f)

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

Attached hereto is the "Sequence Listing" in the above-identified patent application in both printed format and computer readable (ASCII) format on 3.5 inch diskette. I hereby certify that the paper copy and the computer readable copy of the Sequence Listing are identical.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Date: February 8, 2002

By:



Shirley Chen, Ph.D.
Registration No. 44,608

650 Page Mill Road
Palo Alto, California 94304
(650) 493-9300
Client No. 021971